Target Name: MIR425
NCBI ID: G494337
Review Report on MIR425 Target / Biomarker Content of Review Report on MIR425 Target / Biomarker
MIR425
Other Name(s): microRNA 425 | hsa-miR-425-3p | hsa-mir-425 | hsa-miR-425-5p | MicroRNA 425 | mir-425 | MIRN425

MicroRNA 425: A Potential Drug Target and Biomarker

MicroRNA (miRNA) 425 (MIR425) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. MIR425 is a 24.1 kilobase (kb) RNA molecule and is expressed in various tissues and cell types. It is a part of the miRNA family, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation.

MIR425 is characterized by its unique 5' end overlapping structure, which consists of a 26-nt hairpin loop followed by a 7-nt stem-loop and a 110-nt loop. This structure is stable and forms a stable double-stranded RNA molecule. MIR425 has a calculated melting temperature of 59.5掳C, which suggests that it can form a stable double-stranded RNA molecule in the cell.

MIR425 has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis. MIR425 has been shown to be involved in cell proliferation by regulating the expression of various genes. For example, MIR425 has been shown to suppress the expression of the gene encoding the protein p21, which is a cell cycle inhibitor that can prevent cell growth.

MIR425 has also been shown to play a role in cell differentiation and plasticity. For example, MIR425 has been shown to regulate the expression of genes involved in cell adhesion and cell-cell signaling, which are critical processes for cell differentiation and plasticity.

MIR425 has also been shown to play a role in apoptosis, which is the process by which cells die and are removed from the body. MIR425 has also been shown to regulate the expression of genes involved in apoptosis, including the gene encoding the protein Bcl-2 . Bcl-2 is a protein that has been shown to prevent apoptosis and protect cells from stress.

In addition to its role in cellular processes, MIR425 has also been shown to be a potential drug target. The miRNA family of molecules has been shown to be promising targets for drugs because of their small size and the fact that they can interact with various cellular processes. MIR425 is no exception.

One of the potential advantages of MIR425 as a drug target is its small size, which makes it easier to target with small molecules. Another advantage is the fact that MIR425 has been shown to play a role in various cellular processes, which makes it a promising target for drugs that can modulate these processes.

In addition to its potential as a drug target, MIR425 has also been shown to be a potential biomarker. The miRNA family of molecules has been shown to be involved in various biological processes, including cancer, neurodegenerative diseases, and cardiovascular diseases. MIR425 is no exception.

MIR425 has been shown to be involved in the regulation of cellular processes that are associated with disease, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, MIR425 has been shown to play a role in the regulation of cell proliferation and has been shown to be involved in the development of cancer.

In addition to its potential role in cancer, MIR425 has also been shown to be involved in the regulation of neurodegenerative diseases. For example, MIR425 has been shown to play a role in the regulation of the production of neurotransmitters, which are involved in the regulation of mood and appetite.

MIR425 has also been shown to play

Protein Name: MicroRNA 425

The "MIR425 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR425 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316 | MIR4317 | MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B